

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 28, 2010

STEREOTAXIS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-50884

(Commission File Number)

4320 Forest Park Avenue, Suite 100, St. Louis, Missouri

(Address of Principal Executive Offices)

94-3120386

(IRS Employer Identification No.)

63108

(Zip Code)

(314) 678-6100

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On September 28, 2010, executive management of Stereotaxis, Inc. (the “Company”) will present at the Fifth Annual JMP Securities Healthcare Conference. The investor presentation slides are being furnished as Exhibit 99.1 and can be accessed on the Investor Relations portion of the Company’s website at <http://www.stereotaxis.com/Investor-Relations>.

The presentation slides are being furnished pursuant to Item 7.01, and the information contained therein shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The presentation slides that are attached to this Current Report on Form 8-K as Exhibit 99.1 include statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company’s products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

Item 9.01. Financial Statements and Exhibits.

- (d) Exhibits.
- 99.1 Investor presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STEREOTAXIS, INC.

Date: September 28, 2010

By: _____ /s/ DANIEL J. JOHNSTON
Name: Daniel J. Johnston
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit
No.

Document

99.1

Investor presentation



STEREOTAXIS

NASDAQ: STXS

Forward-Looking Statements

During the course of this presentation, the Company may make projections and other forward-looking statements regarding future events or the future financial performance of the Company, including without limitation, statements regarding future operating results, growth opportunities and other statements that refer to Stereotaxis' plans, prospects, expectations, strategies, intentions and beliefs. These statements are subject to many risks and uncertainties that could cause actual results to differ materially from expectations.

For a detailed discussion of risks and uncertainties that affect the Company's business and qualify the forward-looking statements made in this presentation, we refer you to the Company's recent public filings filed with the SEC, specifically the Form 10-K for the fiscal year ended December 31, 2009.

The Company's projections and forward-looking statements are based on factors that are subject to change and therefore these statements speak only as of the date they are given. The Company assumes no obligation to update any projections or forward-looking statements.

In addition, regarding orders and backlog, there can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period, or at all, because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. These orders and commitments may be revised, modified, or canceled either by their express terms, as a result of negotiations, or by project changes or delays.




Investment Considerations

- Two innovative technology platforms:
 - Niobe[®] Magnetic Navigation System
 - Odyssey[™] Enterprise Solutions
- Substantial IP portfolio
- Large, fast growing (+20%) cardiology ablation market
- Poised for continued growth in electrophysiology (EP)
- Expansion into new markets
 - New geographic opportunities
 - Broad clinical applications beyond EP
- Multi-dimensional strategy to accelerate growth




NiobeMagnetic Navigation System

Magnet-guided catheter distal tip provides precise remote control of therapeutic devices.



Niobe Provides Precision and Safety

- ▶ Precise control of catheter distal tip provides:
 - ▶ Effective lesion creation through constant contact
 - ▶ Exceptional mapping capability
- ▶ Exemplary safety
- ▶ Proven in all chambers of the heart



Niobe's Advantages

Niobe



Manual



Physician

In control room outside fluoroscopy field

In procedure room exposed to fluoroscopy

Safety

Physician: Almost no X-ray exposure
Patient: Major event rate ~0.1%

Physician: Significant X-ray exposure
Patient: Major event rate ~2.8%

Efficacy

Clearly better in several applications
- VT, pediatrics, congenital heart diseases
Other applications comparable to manual

High re-do rates

Efficiency


Standardized process drives tighter distribution around procedure times

Higher variability in procedure times




Strong Clinical Validation

More than 150 peer-reviewed publications highlight Niobe's value



Radiation Reduction


Patients – 67%¹
Physicians – 90%²



1. Haghjoo, JCE 2009. 2. Latcu, Arch Cardiovasc Dis 2009. 3. Schwagten, PACE 2009. 4. DiBiase, JCE 2009.
5. Augello, Heart Rhythm 2009. 6. Schwagten, PACE 2009. 7. Haghjoo, JCE 2009. 8. DiBiase, Heart Rhythm 2009.

Major Advantages in Ventricular Tachycardia Ablation

- VT is an abnormally fast heart rhythm that originates from one of the ventricles and can lead to potentially life threatening complications.
- 64 consecutive VT ablation patients
 - 37 Niobe; 27 manual procedures
 - Idiopathic & Scar-Related
- No complications in Niobe group
- 1 tamponade/death in manual group
- **Conclusion: Niobe offers “major clinical & cost advantages for VT ablation”**



Global EP Market is Large and Growing

	<u>EP Procedures</u>	<u>Prevalence</u>	<u>Annual Procedures</u>	<u>Annual Growth</u>
	Routine	>20M	170K	<10%
Stereotaxis focused on complex ablation, high-growth segments	AF	>10M	100K	25%
	VT	>3M	30K	15%
	Other	>5M	40K	15%
	Total Complex	>18M	170K	20%

Source: Millennium Research Group (2009); Stereotaxis internal analysis

NiobeMarket Adoption & Procedure Growth

Growing Worldwide Penetration

141 Systems Installed



Cumulative Procedures

30,000 + procedures




60% US - 40% OUS




Odyssey EnterpriseTM Solutions

Integrates and centralizes all EP lab related information to significantly enhance physicians' efficiency




Odyssey Vision



The Odyssey Product Line

ODYSSEY




Business Model

Capital Revenue

Niobe



Odyssey Workstation



Odyssey Cinema



Recurring Revenue

Capital Driven

- Technical service
- Software license

Niobe Utilization

- Stereotaxis disposables
- Royalty from J&J BWI

- 141 Niobe systems installed
- 2,500 EP labs worldwide
- 20+% growth; ~60% margin

- 25% growth (YTD 2010 vs. 2009)
- 80% margin

27% growth (2009 vs. 2008); 65+% margin



Strategies to Accelerate Growth

Niobe

- Upgrade sales team
- Drive clinical adoption
- Full adoption builds reference sites
- Reference sites accelerate capital sales

Odyssey

- Grow with Niobe
- Penetrate large standard lab market (non-Niobe)
- Dedicated sales force
- Leverage partners


Stereotaxis

- R&D focused on addressing clients needs
- Geographic expansion
- Broaden market opportunities




Stereotax Financial Update


\$ millions **New Orders to Backlog**







\$ millions **Recurring Revenue**




\$ millions **Revenue Momentum**



Stereotax Financial Update




Liquidity



* Cash burn includes repayment of Biosense Webster advance.

Q2 2010 Cash Burn Analysis



Investment Considerations

- Two innovative technology platforms:
 - Niobe[®] Magnetic Navigation System
 - Odyssey[™] Enterprise Solutions
- Substantial IP portfolio
- Large, fast growing (+20%) cardiology ablation market
- Poised for continued growth in electrophysiology (EP)
- Expansion into new markets
 - New geographic opportunities
 - Broad clinical applications beyond EP
- Multi-dimensional strategy to accelerate growth



Q & A

